Sushil Patel serves as the Chief Strategy Officer at Replimune Group Inc., a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies for the treatment of cancer. With over two decades of experience in the biopharmaceutical industry, Patel has established himself as a seasoned executive with a strong track record of driving strategic growth and innovation. Prior to joining Replimune, he held key leadership positions at several prominent companies, including Novartis, where he served as Vice President and Head of Global Oncology Strategy and Operations. At Novartis, Patel played a pivotal role in the successful development and commercialization of several groundbreaking oncology treatments, contributing to the company's position as a leader in the field. His expertise in strategic planning, business development, and portfolio management has been instrumental in guiding Replimune's growth trajectory since joining the company. As Chief Strategy Officer, Patel is responsible for shaping the company's long-term vision and overseeing the execution of its strategic initiatives, including the advancement of its pipeline of innovative therapies and the expansion of its global presence. Under Patel's leadership, Replimune has made significant progress in advancing its lead product candidates through clinical trials and forging strategic partnerships to accelerate the development of its novel therapies. His strategic insights and deep understanding of the oncology landscape have been invaluable in positioning Replimune as a frontrunner in the rapidly evolving field of oncolytic immunotherapy. With his unwavering commitment to improving patient outcomes and his ability to navigate the complexities of the biopharmaceutical industry, Sushil Patel continues to play a crucial role in driving Replimune's mission to transform the treatment of cancer.